SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nyberg Joakim)
 

Sökning: WFRF:(Nyberg Joakim) > Sensitivity of Pegf...

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Brekkan, Ari (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmetheus, Uppsala, Sweden
Plan, Elodie L., 1981- (författare)
Dr. Reddy’s Laboratories, Basel, Switzerland.,Dr Reddys Labs, Basel, Switzerland,Pharmetheus, Uppsala, Sweden
Plan, Elodie L., 1981- (författare)
Pharmetheus, Uppsala, Sweden
visa fler...
Nyberg, Joakim (författare)
Pharmetheus, Uppsala, Sweden.
Kankanwadi, Suresh (författare)
Dr. Reddy’s Laboratories, Basel, Switzerland.,Dr Reddys Labs, Basel, Switzerland
Karlsson, Mats (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmetheus, Uppsala, Sweden
visa färre...
 (creator_code:org_t)
2019-07-08
2019
Engelska.
Ingår i: AAPS Journal. - : Springer. - 1550-7416. ; 21:85
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • In this work, a previously developed pegfilgrastim (PG) population pharmacokinetic-pharmacodynamic (PKPD) model was used to evaluate potential factors of importance in the assessment of PG PK and PD similarity. Absolute neutrophil count (ANC) was the modelled PD variable. A two-way cross-over study was simulated where a reference PG and a potentially biosimilar test product were administered to healthy volunteers. Differences in delivered dose amounts or potency between the products were simulated. A different baseline absolute neutrophil count (ANC) was also considered. Additionally, the power to conclude PK or PD similarity based on areas under the PG concentration-time curve (AUC) and ANC-time curve (AUEC) were calculated. Delivered dose differences between the products led to a greater than dose proportional differences in AUC but not in AUEC, respectively. A 10% dose difference from a 6 mg dose resulted in 51% and 7% differences in AUC and AUEC, respectively. These differences were more pronounced with low baseline ANC. Potency differences up to 50% were not associated with large differences in either AUCs or AUECs. The power to conclude PK similarity was affected by the simulated dose difference; with a 4% dose difference from 6 mg the power was approximately 29% with 250 subjects. The power to conclude PD similarity was high for all delivered dose differences and sample sizes.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

biosimilarity
exposure sensitivity
granulocyte colony-stimulating factor
pegfilgrastim
population pharmacokinetic-pharmacodynamic modelling

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy